Vytrus Biotech, S.A. (FRA:V5P)

Germany · Delayed Price · Currency is EUR

16.70

-0.90 (-5.11%)

Last updated: Aug 26, 2026, 3:25 PM CET

212.15% (1Y)

Market Cap	128.53M +194.5%
Revenue (ttm)	9.69M +59.1%
Net Income	2.90M +183.7%
EPS	0.39 +184.0%
Shares Out	n/a
PE Ratio	44.37
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Open	16.75
Previous Close	17.60
Day's Range	16.70 - 17.40
52-Week Range	4.78 - 21.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 9, 2026

About Vytrus Biotech

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin’s regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and protects ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2009

Employees 44

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol V5P

Financial Performance

In 2025, Vytrus Biotech's revenue was 9.69 million, an increase of 59.15% compared to the previous year's 6.09 million. Earnings were 2.90 million, an increase of 183.70%.

Financial Statements